Live Roundups Editor's Desk Insights Executive Ops Weather About 🔍
Home › Business & Finance › Jio Keeps Ambani Magic Alive as Investors Await Earnings
Business & Finance

Jio Keeps Ambani Magic Alive as Investors Await Earnings

Bloomberg Markets Friday 30 October 2026, 05:30 UTC 1 min read
Key Points

Oct 30th, 2026 Jio Keeps Ambani Magic Alive as Investors Await Earnings Jio Platforms’ strong post-listing performance may continue in the coming weeks, supported by limited competition in India’s telecom market. Investors now look for cues from the company's second-quarter earnings on Friday. Menaka Doshi explains.

Oct 30th, 2026 Jio Keeps Ambani Magic Alive as Investors Await Earnings Jio Platforms’ strong post-listing performance may continue in the coming weeks, supported by limited competition in India’s telecom market. Investors now look for cues from the company's second-quarter earnings on Friday. Menaka Doshi explains.
Jio Keeps (PERSON) Ambani Magic (PERSON) India (LOCATION) Menaka Doshi (PERSON)
Originally published by Bloomberg Markets Read original →

Related Stories

P&R urged to speed up review of relocation grants

Forward Guernsey believes the allowance is putting pressure on rental prices.

BBC Business 15m ago

Opening the EU debate again is clearly a political minefield. But we have to do it | Simon Jenkins

Andy Burnham must tread cautiously, but Brexit was a very grave act of self-harm – and he is right to address itAndy Burnham’s opening debate on whether Britain should rejoin the EU is divisive, painful and politically risky. That is why it should be welcomed. To jeopardise his popularity so soon after coming to office might seem reckless, but the issue is urgent and not going away.

The Guardian UK 32m ago

Opening the EU debate again is clearly a political minefield. But we have to do it | Simon Jenkins

Andy Burnham must tread cautiously, but Brexit was a very grave act of self-harm – and he is right to address itAndy Burnham’s opening debate on whether Britain should rejoin the EU is divisive, painful and politically risky. That is why it should be welcomed. To jeopardise his popularity so soon after coming to office might seem reckless, but the issue is urgent and not going away.

The Guardian Politics 32m ago

A pharma giant is moving past one patent cliff — but another is already looming

"This medicine could be one of our largest medicines in history," Novartis CEO Vas Narasimhan told CNBC on Tuesday, as the Swiss drugmaker backed remibrutinib, its experimental MS medicine, to generate more than $4 billion in peak annual sales. Days before, Barclays cut its forecast for the drug's peak sales after detailed results from two late-stage trials showed the drug had reduced relapses in MS patients by less than analysts expected. It highlights a challenge for Novartis as it...

CNBC 33m ago